CoCo Therapeutics Ltd Announces Appointment of Steve Butcher as Chief Operating Officer

CoCo Therapeutics Ltd announced the appointment of Dr Steve Butcher as Chief Operating Officer.

London UK, March 7, 2013 / B3C newswire / - CoCo Therapeutics Ltd, a newly formed biotechnology company, today announced the appointment of Dr Steve Butcher as Chief Operating Officer. Dr Butcher was a founder and Scientific Director of the Fujisawa Institute of Neuroscience, before holding management positions of increasing responsibility at Pharmacia AB. More recently he held executive positions in a number of biotechnology companies, including CSO at BioImage A/S and COO at TopoTarget A/S.
Raj Parekh, General Partner at Advent Venture Partners and the Chairman of CoCo said "We are pleased that an individual of Steve’s calibre is now leading the programmes at CoCo Therapeutics. The Board looks forward to working closely with Steve to evaluate RAR-alpha agonists in Alzheimer's disease."

Alzheimer’s disease (AD) is the most common cause of dementia, affecting around 5.3 million people in the US, 417,000 people in the UK and many millions of others worldwide. It is estimated that this incidence will more than double by 2050, should current trends continue.